Vivek Reddy details several key late-breakers at HRS 2026

 

Vivek Reddy, MD, a leading figure in electrophysiology (EP), presented new data related to pulsed field ablation (PFA) and leadless conduction system pacing at Heart Rhythm 2026 in Chicago.

Reddy, director of the cardiacarrhythmia service line and a professor of cardiac EP with Icahn School of Medicine at Mount Sinai, spoke to Cardiovascular Business during the conference about what these technologies could mean for the future of patient care.

LEAP2 study tests new Abbott leadless conduction pacing system

Among the most closely watched presentations during Heart Rhythm 2026 was the LEAP 2 first-in-human trial evaluating a novel leadless pacemaker designed for conduction system pacing—an area that has remained a major limitation for current leadless devices.

“We know that leadless pacemakers are very effective tools. They're very safe and they work very well as pacemakers and patients like them and not having a scar,” Reddy explained. “But one of the biggest limitations of leadless pacemakers has been the inability to do conduction system pacing.”

The investigational LPCSP system is an Abbott Aveir leadless pacemaker that was modified with an extended electrode protruding about 1 centimeter from the tip to target the left bundle branch area pacing. The device is implanted through the internal jugular vein using a deflectable sheath positioned across the tricuspid valve.